The effect of enoxaparin on sudden sensorineural deafness

Evaluation the effectiveness of treatment with enoxaparin as adjunctive therapy in the treatment of patients with idiopathic retention sensorineural hearing loss

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20211010052721N2

Enrollment

Registered

2022-06-27

Start date

2022-07-21

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sudden sensorineural hearing loss. Sensorineural hearing loss, bilateral

Interventions

Intervention 1: Intervention group: In the intervention group, oral prednisolone (1 mg / kg) for 10 days and dexamethasone in the ear (5 mg / ml) for a total of 10 times daily plus, 1 mg / kg subcutan

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Conscious consent to participate in the study Patients with sudden sensorineural hearing loss that progresses rapidly and no known cause is found for more than 72 hours

Exclusion criteria

Exclusion criteria: History of ear diseases Patients with contraindications to treatment with systemic corticosteroids or anticoagulants such as diabetes mellitus History of intermittent hearing loss Pregnancy Breastfeeding

Design outcomes

Primary

Measure	Time frame
Average hearing threshold. Timepoint: Before the intervention and 10 days after starting taking enoxaparin. Method of measurement: Audiometry.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNavid Nourizadeh

Mashhad University of Medical Sciences

nourizadehn@mums.ac.ir+98 51 3841 3492

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026